CD19 and acute lymphoblastic leukemia: A total of 10 patients (median age, 41.3 years; minimum, 28 years; maximum, 51 years; 7 men and 3 women) with Ph+ ALL were included, all of whom were received CD19/22 cocktail CAR-T therapy.